Histological improvement in salivary gland along with effector memory Th17-1 cell reduction in a primary Sjogren's syndrome patient with dermatomyositis and diffuse large B-cell lymphoma by R-CHOP therapy

Koga, Tomohiro; Mizokami, Akinari; Nakashima, Masahiro; Shimizu, Toshimasa; Nakashima, Yoshikazu; Nakamura, Hideki; Chiwata, Masahiko; Niino, Daisuke; Kawakami, Atsushi

doi:10.1016/j.clim.2016.03.005

Cited by 5 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reduced frequencies and numbers of cTfh cells and Th17 cells during B cell depletion are accompanied by decreased serum levels of IL-21 and IL-17. Th17 cells in minor salivary glands are also reduced by rituximab, but the effect on local Tfh cells is not known yet [37,38]. Depletion of the small fraction of Th17 cells that co-expresses CD20 may contribute to the decrease in Th17 cells [39].…”

Section: Effects Of Rituximab On the Cd4 + T Cell Compartmentmentioning

confidence: 99%

The value of rituximab treatment in primary Sjögren's syndrome

Verstappen

Nimwegen

Vissink

et al. 2017

Clinical Immunology

View full text Add to dashboard Cite

Section: Effects Of Rituximab On the Cd4 + T Cell Compartmentmentioning

confidence: 99%

The value of rituximab treatment in primary Sjögren's syndrome

Verstappen

Nimwegen

Vissink

et al. 2017

Clinical Immunology

View full text Add to dashboard Cite

“…After reviewing the relevant literature, we only identified 117 cases of SS‐related DLBCL that have been described in case reports or small case series . This very small sample size is likely related to the low prevalence of pSS in the general population, which is estimated to be 0.2%–1.4%, combined with the estimated incidence of DLBCL, which is 7/100 000 population .…”

Section: Discussionmentioning

confidence: 99%

Characteristics of diffuse large B‐cell lymphoma in patients with primary Sjögren's syndrome

2020

View full text Add to dashboard Cite

Aim: Patients with primary Sjögren's syndrome (pSS) have an increased risk of developing diffuse large B-cell lymphoma (DLBCL), which is an aggressive and heterogeneous non-Hodgkin lymphoma. This study aimed to characterize DLBCLs in patients with pSS. Method: We identified 18 patients with DLBCL and pSS over a 22-year period. Based on the 2016 WHO guidelines, we characterized DLBCL based on immunohistochemical tests using a broad panel of antibodies, and an Epstein-Barr virus (EBV) test using in situ hybridization. Results: The median time from initial pSS symptom onset to the DLBCL diagnosis was 20.5 years and the median time from the pSS diagnosis until the DLBCL diagnosis was 14 years. After the lymphoma diagnosis, the median overall survival was 3 months (range: 0-212 months) and the 5-year overall survival rate was 37.5%. Thirteen DLBCLs were re-classified as DLBCL, not otherwise specified (NOS) in nine cases; EBV-positive DLBCL, NOS in two cases; and T-cell/histiocyte-rich large B-cell lymphoma in two cases. Five cases of DLBCLs were not re-classified because theirEBV status was unknown. The Hans algorithm, which uses a combination of staining for CD10, BCL6, and MUM1, was used to classify the DLBCLs into the germinal center B-cell (GCB) subtype for three cases and the non-GCB subtype for nine cases. Conclusion:These results indicate that DLBCL tends to occur late in pSS cases and is mainly related to the non-GCB subtype of DLBCL.

show abstract

Th17.1 lymphocytes: emerging players in the orchestra of immune-mediated inflammatory diseases

Misra

Agarwal

2022

Clin Rheumatol

View full text Add to dashboard Cite

Histological improvement in salivary gland along with effector memory Th17-1 cell reduction in a primary Sjogren's syndrome patient with dermatomyositis and diffuse large B-cell lymphoma by R-CHOP therapy

Cited by 5 publications

References 9 publications

The value of rituximab treatment in primary Sjögren's syndrome

The value of rituximab treatment in primary Sjögren's syndrome

Characteristics of diffuse large B‐cell lymphoma in patients with primary Sjögren's syndrome

Th17.1 lymphocytes: emerging players in the orchestra of immune-mediated inflammatory diseases

Contact Info

Product

Resources

About